MSN: MannKind (MNKD) upgraded to strong buy: Here's what you should know
Investors might want to bet on MannKind (MNKD), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. MannKind (MNKD) is a stock that can certainly grab the attention ...
We came across a bullish thesis on MannKind Corporation on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on MNKD. MannKind Corporation’s share was trading at $3.5000 as of ...
MSN: MannKind slides after halting late-stage trial of MNKD-101 for lung disease
MannKind Corporation (MNKD) saw a stock decline after the announcement that it would discontinue its trial testing MNKD-101, a nebulized form of clofazimine intended for treating refractory ...
Insider Monkey: MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
We recently published 12 Best Healthcare Stocks to Buy Under $30. MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare stocks. MannKind Corporation (NASDAQ:MNKD)’s most recent milestone is ...
StockNews.com upgraded shares of MannKind (NASDAQ:MNKD – Free Report) from a hold rating to a buy rating in a research note released on Wednesday. A number of other research analysts also recently ...
MannKind Corporation (NASDAQ:MNKD) are trading lower Monday. The company released its six-month results from its Phase 3 INHALE-1 pediatric diabetes trial. Here’s what you need to know. What To Know: ...